Veille documentaire MTPH

Auteur     Eva Hong
Auteur     Aude Terrade
Auteur     Muhamed-Kheir Taha
Volume     13
Numéro     3
Pages     645-648
Publication     Human Vaccines & Immunotherapeutics
ISSN     2164-554X
Date     Mar 04, 2017
Résumé     Neisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon the licensure in Europe of Bexsero® vaccine. We tested the immunogenicity and safety of this vaccine among adults laboratory staff using the recommended schedule of 2 doses at 5 weeks interval. The vaccine was well tolerated in spite of frequent local side effects and all participants reported at least one side effect after each dose. Immunogenicity was evaluated 6 weeks and one year after the second dose. All participants showed increase in their bactericidal titers against the components of the vaccine 6 weeks after the second dose, however titers declined significantly one year later.